Last reviewed · How we verify
fibrinolysis
At a glance
| Generic name | fibrinolysis |
|---|---|
| Also known as | Primary PCI |
| Sponsor | Holger Thiele |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke (NA)
- SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial (PHASE2)
- Early Catheter-directed Treatment of High Risk Pulmonary Embolism (NA)
- Optimal Time for Reperfusion in Acute Pulmonary Embolism
- Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
- Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion (ETICA) (NA)
- Lumbar Drainage of Intraventricular Hemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fibrinolysis CI brief — competitive landscape report
- fibrinolysis updates RSS · CI watch RSS
- Holger Thiele portfolio CI